Key Takeaways Large-cap pharma has beaten the S&P 500 lately as pricing deals, M&A and innovation revive investor sentiment.Eli Lilly, J&J, AbbVie, Amgen and AstraZeneca all posted strong 2025 gains on key drugs and pipeline. Despite patent cliffs and regulatory risks, innovation, AI use and deal momentum support a solid 2026 outlook.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administrat ...

alengo / E+ via Getty Images One question about how likely a company is to raise its dividend next year is whether it has already raised it for decades. If one is willing to posit that, several companies are likely candidates. 24/7 Wall St. Key Points These four companies have increased their dividends annually for decades. And they will mostly likely boost their payouts again in the coming year. If you’re thinking about retiring or know someone who is, there are three quick questions causing many ...

Core Insights - Dividend Kings are companies that have increased their dividend payments for at least 50 consecutive years, providing a reliable long-term investment strategy [1] - Several Dividend Kings, including Coca-Cola, Johnson & Johnson, and Consolidated Edison, have achieved over 100% total return in the past decade, suggesting a potential for doubling investments in the next 10 years through a buy-and-hold strategy [1] Group 1: Coca-Cola - Coca-Cola increased its dividend payment by 5.2% this year, marking its 63rd consecutive year of dividend growth [3] - The company has delivered a total return of approximately 125% over the past decade, equating to an annualized return of 8.4% [3][4] - Coca-Cola aims for organic revenue growth of 4% to 6% per year and high-single-digit earnings-per-share growth, supported by a strong balance sheet and significant investments in product innovation and marketing [4][5] Group 2: Johnson & Johnson - Johnson & Johnson raised its dividend payment by 4.8% this year, also extending its dividend growth streak to 63 years [6] - The company has achieved a total return exceeding 165% over the past decade, with an annualized return of 10.3% [6] - Johnson & Johnson holds a AAA bond rating, indicating a strong financial profile, and consistently produces resilient earnings [8]

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her peritoneal mesothelioma, a form of cancer.Jurors in the Circuit Court for Baltimore City, Maryland, on Monday found the company, two of its subsidiaries and spinoff Kenvue liable for failing to warn plaintiff Cherie Craft that its baby powder contained asbestos. Johnson & Johnson said it will appeal the jury’s decision ...

Key Takeaways JNJ secured FDA approval for subcutaneous Rybrevant Faspro across all existing NSCLC indications.The SC version cuts administration time to about five minutes versus up to several hours for IV delivery.Approval was backed by PALOMA-3 data showing Rybrevant Faspro was at least as effective as IV therapy.Johnson & Johnson (JNJ) announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be ma ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - A Baltimore jury has ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who alleged that long-term exposure to asbestos in the company's talc-based products led to her diagnosis of peritoneal mesothelioma, a type of cancer [1] Group 1 - The jury's decision highlights ongoing legal challenges faced by Johnson & Johnson regarding the safety of its talc-based products [1] - The case underscores the potential health risks associated with asbestos exposure linked to consumer products [1] - This ruling may have significant financial implications for Johnson & Johnson, impacting its overall market position and investor confidence [1]

Core Viewpoint - A Baltimore jury awarded Cherie A. Craft over $1.5 billion after determining that Johnson & Johnson and its subsidiaries exposed her to asbestos through talc-based personal care products, leading to her diagnosis of peritoneal malignant mesothelioma, an incurable cancer. This verdict is noted as the largest ever against Johnson & Johnson for a single plaintiff [1]. Group 1 - The jury's verdict in favor of Cherie A. Craft is significant, marking a potential turning point in legal challenges against Johnson & Johnson regarding their talc products [1]. - The amount awarded, over $1.5 billion, highlights the severity of the case and the implications for Johnson & Johnson's financial liabilities [1]. - The diagnosis of peritoneal malignant mesothelioma, linked to asbestos exposure, raises concerns about the safety of talc-based products in the personal care industry [1].

A jury ordered Johnson & Johnson to pay about $1.56 billion to a Maryland woman who blamed the company’s talc-based baby powder for causing her asbestos-linked cancer https://t.co/UV5V04LyS3 ...

Key Takeaways U.S. healthcare challenged the S&P 500 in 2025, with biotech leading as the industry index rose 23.2%. GLP-1 drug breakthroughs, AI-driven efficiency and strong earnings beats fueled the sector's rally. ETF exposure offers diversified access as M&A activity and demographic tailwinds support 2026 growth. As we approach the final weeks of 2025, the U.S. healthcare sector has transitioned from a defensive stalwart to a primary market leader. Evidently, while the S&P 500 has delivered a solid ret ...